The upregulation of miR-21-5p in atherosclerotic plaque
- PMID: 40627217
- DOI: 10.1007/s11033-025-10790-y
The upregulation of miR-21-5p in atherosclerotic plaque
Abstract
Background: Atherosclerosis refers to a complex arterial condition characterized by inflammation and vascular remodeling leading to plaque formation. It is driven by dysregulated inflammatory pathways, endothelial dysfunction, and abnormal cholesterol metabolism associated with lifestyle risk factors. Because atherosclerosis is a major heart disease risk factor, identifying biomarkers is critical. MicroRNAs regulate gene expression and are implicated in disease pathogenesis. This study investigates the roles of miR-193b-3p, miR-21-5p, and miR-484 in atherosclerotic plaque pathogenesis.
Methods & results: A gene expression analysis was performed utilizing the reverse RT-qPCR (transcription-quantitative polymerase chain reaction) technique on samples collected from atherosclerotic plaques in the carotid artery (CAP tissue) and non-atherosclerotic internal mammary arteries (IMA tissue) of 50 patients diagnosed with both coronary artery disease and carotid artery disease. A marked difference was found in the levels of miR-21-5p (p = 0.0001), with CAP tissue showing a 21.96-fold increase in miR-21-5p expression compared to IMA tissue. In contrast, the expression levels of the miR-193b-3p and miR-484 genes did not exhibit any significant differences between the CAP and IMA samples. In CAP tissue, there were strong positive correlations observed between miR-193b-3p and miR-484 (r = 0.99, p < 0.0001), miR-484 and miR-21-5p (r = 0.83, p < 0.0001), and miR-193b-3p and miR-21-5p (r = 0.77, p < 0.0001).
Conclusions: Altering miRNA expression in the artery offers a promising approach to impact plaque formation through multiple mechanisms, all by targeting a single molecule. Nevertheless, additional studies are required to validate the pharmacological and diagnostic capabilities of these miRNAs.
Keywords: Atherosclerotic plaques, miR-21-5p; miR-193b-3p; miR-484.
© 2025. The Author(s), under exclusive licence to Springer Nature B.V.
Conflict of interest statement
Declarations. Ethical approval: The ethical approval was obtained from Istanbul University-Cerrahpasa Cerrahpasa Medical School Institutional Review Board with the serial code of 89090. All of the procedures on human participants were in accordance with the declaration of Helsinki in 1964, its amendments and parallel ethical standards. Competing interests: The authors declare no competing interests. Consent to participate: All participants were informed with written consent form before participation to the study.
References
-
- -Gusev E, Sarapultsev A (2023) Atherosclerosis and inflammation: insights from the theory of general pathological processes. Int J Mol Sci 24:7910. https://doi.org/10.3390/ijms24097910 - DOI - PubMed - PMC
-
- -Raskurazhev AA, Kuznetsova PI, Shabalina AA, Tanashyan MM (2022) MicroRNA and hemostasis profile of carotid atherosclerosis. Int J Mol Sci 23:10974. https://doi.org/10.3390/ijms231810974 - DOI - PubMed - PMC
-
- -Sekar D, Saravanan S, Karikalan K, Thirugnanasambantham K, Lalitha P, Islam VI (2015) Role of MicroRNA 21 in mesenchymal stem cell (MSC) differentiation: a powerful biomarker in MSCs derived cells. Curr Pharm Biotechnol 16:43–48. https://doi.org/10.2174/138920101601150105100851 - DOI - PubMed
-
- -Surina S, Fontanella RA, Scisciola L, Marfella R, Paolisso G, Barbieri M (2022) miR-21 in human cardiomyopathies. Front Cardiovasc Med 9:913429. https://doi.org/10.3389/fcvm.2022.913429 - DOI - PubMed - PMC
-
- -Khordadmehr M, Shahbazi R, Sadreddini S, Baradaran B (2019) miR-193: A new weapon against cancer. J Cell Physiol 234:16861–16872. https://doi.org/10.1002/jcp.28368 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous